spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  retinal vein occlusion 

 HSMN NewsFeed - 21 May 2024
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili(TM). Enters U.S. Ophthalmology Market
Biopharmaceuticals Generics Ophthalmology FDA
 HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 8 Aug 2022
Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 29 Jun 2022
EYLEA(R) (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Apr 2022
Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY(TM) (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 2 Dec 2019
Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 13 Aug 2019
FDA Approves EYLEA(R) (aflibercept) Injection Prefilled Syringe
Biopharmaceuticals Drug Delivery Ophthalmology FDA
 HSMN NewsFeed - 17 Jul 2019
U.S. FDA Accepts Allergan's New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 25 Oct 2018
EYLEA(R) (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 Sep 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 17 Aug 2018
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 13 Aug 2018
Regeneron Provides Regulatory Update on EYLEA(R) (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jul 2018
Oculocare's Alleye(R) Receives FDA 510(k) Clearance for Monitoring Eyesight in AMD
Devices Diagnostics Ophthalmology FDA
 HSMN NewsFeed - 19 Mar 2018
EYLEA(R) (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 14 Feb 2018
Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 11 Dec 2017
Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA(R) (aflibercept) Injection for Patients with Wet AMD
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 27 Nov 2017
Regeneron Provides Update on EYLEA(R) (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 Oct 2016
Ocular Therapeutix(TM) and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 11 Oct 2016
FDA Grants Priority Review to Genentech’s Lucentis(R) (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 3 Dec 2015
Clearside Biomedical, Inc. Completes $20 Million Series C Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 30 Oct 2015
Regeneron Announces EU Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 5 Aug 2015
Ohr Pharmaceutical Promotes Jason S. Slakter, MD to Chief Executive Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 26 Jun 2015
EYLEA(R) (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 26 Feb 2015
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 17 Oct 2014
EYLEA(R) (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 29 Sep 2014
Allergan Announces FDA Approves Revised Indication for OZURDEX(R) (dexamethasone intravitreal implant) 0.7 mg for the Treatment of Diabetic Macular Edema
Biopharmaceuticals Ophthalmology Drug Delivery FDA
 HSMN NewsFeed - 22 Sep 2014
Regeneron Announces EYLEA(R) (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 11 Aug 2014
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 30 Jun 2014
Allergan Announces R&D Pipeline Update and U.S. FDA Approval; Company to Host Conference Call Today, Monday, June 30th at 10:30 AM ET
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 27 Jun 2014
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 23 Apr 2014
Kala Pharmaceuticals Announces $22.5 Million Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 10 Feb 2014
Two-Year Results From Phase 3 VISTA Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 18 Dec 2013
Regeneron Announces FDA Acceptance of EYLEA(R) (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 22 Nov 2013
EYLEA(R) (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 15 Nov 2013
Lumenis Receives US FDA and Japanese MHLW Clearance for Array(TM) LaserLink(TM) Pattern Scanning Device for Multi-Spot Retinal Laser Treatment
Devices Ophthalmology FDA Regulatory
 HSMN NewsFeed - 26 Jul 2013
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 19 Feb 2013
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Dec 2012
EYLEA(R) (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 27 Nov 2012
EYLEA(R) (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 30 Aug 2012
Aerpio Therapeutics Completes $27 Million Series A Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 26 Jul 2012
FDA Advisory Committee Unanimously Recommends Approval of Lucentis for Treatment of Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology Endocrinology FDA
 HSMN NewsFeed - 8 Mar 2012
Regeneron and Bayer Announce Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 12 Dec 2011
10-Year Study Demonstrates IRIDEX MicroPulse(TM) Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
Devices Ophthalmology
 HSMN NewsFeed - 6 Jun 2011
ZALTRAP (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Apr 2011
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Apr 2011
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 25 Mar 2011
Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 10 Mar 2011
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Feb 2011
Lucentis Phase III Study Meets Primary Endpoint for Improving Vision in Patients With Diabetic Macular Edema (DME)
Biopharmaceuticals Endocrinology Ophthalmology
 HSMN NewsFeed - 11 Jan 2011
Dyax and Sigma-Tau Group Expand Agreement to Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema
Biopharmaceuticals Licensing
 HSMN NewsFeed - 20 Dec 2010
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 15 Nov 2010
Christine A. Poon Elected to Regeneron Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Aug 2010
Data from First Phase 3 Trial (EDEMA3(R)) for KALBITOR(R) (ecallantide) Published in The New England Journal of Medicine
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2010
Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 29 Jan 2010
Study Published in the American Journal of Ophthalmology Examines Investigational Use of Macugen in Patients With Branch Retinal Vein Occlusion (BRVO)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Dec 2009
Dyax Announces FDA Approval of KALBITOR(R) (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jul 2009
Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 18 Jun 2009
Allergan Receives FDA Approval for OZURDEX Biodegradable, Injectable Steroid Implant with Extended Drug Release for Retinal Disease
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 30 Apr 2009
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 10 Feb 2009
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 23 Jun 2008
EyeCyte, Inc. Secures Series A Funding from Pfizer
Biopharmaceuticals Regenerative Medicine Venture Capital
 HSMN NewsFeed - 25 Sep 2006
OptiMedica Announces Clinical Outcomes of 1,200 Patients Treated with PASCAL Method of Photocoagulation
Devices Ophthalmology
 HSMN NewsFeed - 1 Jun 2006
Preliminary Topline Efficacy Results from Phase II Data Show Macugen(R) (pegaptanib sodium injection) Maintained or Improved Vision in over 90 Percent of Patients with Macular Edema Associated with Central Retinal Vein Occlusion (CRVO)
Biopharmaceuticals Ophthalmology
Return to NewsFeed  

 Additional items found! 16

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 16 additional stories matching:
retinal vein occlusion
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.